Find out what you know about which diabetes drugs in which classes show CV protective properties and results of the trials that support their use.
Recent Recreational Drug Use Ups Risk of Repeat Serious CV Event: Daily Dose
Your daily dose of the clinical news you may have missed.
Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care
Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.
Survodutide: Novel GCGR/GLP-1RA Shows Promise in Obesity, MASH Treatment
EASD 2024: New data shows survodutide may be beneficial for persons with obesity and MASH.
Primary Viewpoints Episode 4: Lp(a): The Next CVD Target?
Patrick Moriarty, MD, from the University of Kansas Medical Center, discusses the role of Lp(a) as a risk factor for cardiovascular disease and the phase 3 trials of a potential treatment.
Efsitora Alfa, Eli Lilly’s Once Weekly Insulin, Has Positive Topline Results in Two Trials
Across two clinical trials in the QWINT program, once-wekly efsitora showed comparable A1C reduction to frequently used daily insulins.
Finerenone Improves Outcomes in Patients with Heart Failure and Mildly Reduced or Preserved Ejection Fraction
ESC 2024: Findings from the FINEARTS-HF clinical trial provide the first definite evidence that an MRA can be beneficial in patients with HFmrEF/HFpEF.